A 58-year-old man from rural Maharashtra undergoes curative-intent gastrectomy for gastric cancer. Intraoperatively, the surgeon must decide between D1 and D2 lymphadenectomy. Which finding at the time of surgery best distinguishes a tumour likely to benefit from D2 dissection (stage IB–IIIC) from one where D1 alone is adequate (stage IA)?

Explanation

## D1 vs D2 Lymphadenectomy: Surgical Decision-Making in Gastric Cancer ### TNM Staging and Lymphadenectomy Extent **Key Point:** The extent of lymphadenectomy (D1 vs D2) should be guided by the depth of tumour invasion (T-stage) and the presence of lymph node metastases (N-stage). D2 dissection is indicated for T2–T4 tumours with evidence of nodal involvement, whereas D1 is adequate for T1 tumours without nodal disease. ### Decision Algorithm ```mermaid flowchart TD A[Gastric cancer at surgery]:::outcome --> B{T-stage assessment}:::decision B -->|T1 only<br/>no nodes| C[D1 lymphadenectomy]:::action B -->|T2-T4 OR<br/>N+ disease| D[D2 lymphadenectomy]:::action C --> E[Stage IA<br/>5-yr survival ~90%]:::outcome D --> F[Stage IB-IIIC<br/>5-yr survival 20-70%]:::outcome G[Peritoneal metastases<br/>or perforation]:::urgent --> H[Palliative approach]:::action ``` ### Staging & Lymphadenectomy Table | Stage | T-Stage | N-Stage | Recommended Dissection | 5-Year Survival | | --- | --- | --- | --- | --- | | **IA** | T1 | N0 | D1 adequate | ~90% | | **IB** | T2 N0 or T1 N1 | N0–N1 | D2 preferred | 70–80% | | **II** | T3 N0 or T2 N1–N2 | N1–N2 | D2 preferred | 50–60% | | **IIIA** | T4a N0–N1 or T3 N2 | N0–N2 | D2 preferred | 30–40% | | **IIIB/IIIC** | T4b or any T with N3 | N3 | D2 preferred | 10–25% | | **IV** | Any T with M1 | Any N | Palliative | <5% | ### Clinical Pearls **High-Yield:** The **MAGIC trial** (2009) and **D2 trial** (2015) demonstrated that D2 lymphadenectomy improves long-term survival in stages IB–III compared to D1, but adds morbidity. D1 is adequate for early T1N0 disease because the risk of occult nodal metastases is <5%. **Clinical Pearl:** Intraoperative assessment of lymph nodes is imperfect; palpable nodes may be inflammatory, and microscopic metastases are missed. However, **visible N1–N3 disease (perigastric or regional nodes with macroscopic involvement) is the strongest intraoperative indicator that D2 dissection is warranted**. **Warning:** Do not confuse tumour size with T-stage. A 5 cm tumour limited to the mucosa (T1) is stage IA and requires only D1; a 2 cm tumour invading the muscularis propria (T2) is stage IB and requires D2. **Mnemonic:** **D2 for Deeper invasion & Distant nodes** — if the tumour breaches the submucosa (T2+) or you see nodal metastases, perform D2. ### Why This Discriminates The **presence of metastatic perigastric lymph nodes (N1–N3)** is the single most important intraoperative finding that mandates D2 dissection. This finding indicates stage IB–IIIC disease with a significantly worse prognosis than stage IA, and extended nodal dissection is the standard of care to achieve R0 resection and improve survival. [cite:Harrison 21e Ch 297; AJCC Cancer Staging Manual 8e]